Replies to post #23 on BIOWATCH

[BioSpecialist]

re IGXT ..Profitable by next year !!!!

http://www.intelgenx.com/_assets/pdf/Intelgenx-Presentation-2009.pdf

[BioSpecialist]

US approval in 4Q 2009 ??

I hope so ...

http://reports.finance.yahoo.com/w0?r=45713429:2

Developments Intelgenx announced that the FDA has finished its preliminary review and accepted Intelgenx’s NDA filing for CPI-300, a 450mg extended release Bupropion tablet. Impact Positive. Intelgenx is keeping to its timeline and we should see the tablet approved by Q4/09 and on the market by Q1/10. Comments The FDA has begun its full review of Intelgenx’s 450mg Bupropion tablet, which is excellent news for the company and maintains their timeline.